Cardiovascular chief Joerg Koglin (Merck)
Merck makes good on big CV gamble with vericiguat nod — but competition will be fierce
The results for Merck’s leading heart drug fell short of what some cardiologists had hoped for, but they proved more than enough to convince the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
